Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mGluR5 in the Antidepressant Mechanism of CBT-I
NCT07076342Phase 4Recruiting
- Sponsor
- Stony Brook University
- Start
- Aug 2025
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in major depressive disorder (MDD) and Insomnia, sponsored by Stony Brook University. Primary endpoints: Change in Sleep Latency at 8 weeks and Change in mGluR5 density in the hippocampus at 8 weeks. Started Aug 2025; status: recruiting.
02
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT07076342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076342.